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Essentials
• Immunity and coagulation are linked during sepsis but the role of thrombin is not fully elucidated.
• We investigated the effect of thrombin inhibition on murine Klebsiella pneumosepsis outcome.
• Thrombin is crucial for survival and limiting bacterial growth in pneumonia derived sepsis.
• Thrombin improves host defense via fibrin and enhancement of platelet-neutrophil interactions.
Summary. Background: Innate immunity and coagulation are closely linked during sepsis. Their interaction can be detrimental to the outcome because of microvascular failure but can also enhance host defense. The role of thrombin therein has not been fully elucidated. Objective: We aimed to investigate the contribution of thrombin to the host response during pneumonia-derived sepsis. Methods: Mice treated with the specific thrombin inhibitor dabigatran or control chow were infected with the common human sepsis pathogen Klebsiella (K.) pneumoniae via the airways. In subsequent infection experiments, mice were additionally treated with ancrod to deplete fibrinogen. Ex vivo Klebsiella growth was assessed by incubating human whole blood or specific blood components in various conditions with Klebsiella. Results: Thrombin inhibition by dabigatran enhanced bacterial outgrowth and spreading, and accelerated mortality. Thrombin inhibition did not influence neutrophil recruitment to the lung or activation or neutrophil extracellular trap formation. Dabigatran reduced D-dimer formation and fibrin deposition in the lung. Fibrin depletion also enhanced bacterial outgrowth and spreading, and thrombin inhibition had no additional effect. Both thrombin and fibrin polymerization inhibited ex vivo Klebsiella outgrowth in human whole blood, which was neutrophil dependent, and the effect of thrombin required the presence of platelets and platelet protease activated receptor-1. In vivo thrombin inhibition reduced platelet-neutrophil complex formation and endothelial cell activation, but did not prevent sepsisinduced thrombocytopenia or organ damage. Conclusions: These results suggest that thrombin plays an impor
Introduction
Sepsis is the consequence of a dysregulated host response to infection resulting in organ injury [1] . Activation of inflammation and coagulation are closely linked during sepsis [2, 3] . Not only does inflammation lead to a procoagulant state, but in return coagulation augments inflammation. These interactions can be detrimental to outcome and survival, and enhanced coagulation contributes to microvascular failure and subsequent multiple organ failure in settings of hyperinflammation [4] . In accordance, numerous preclinical studies reported a benefit of inhibiting the interaction between inflammation and coagulation in sepsis, for instance by inhibiting protease activated receptors (PARs) [5, 6] or tissue factor (TF) [7, 8] , or by supplementing anticoagulant proteins such as activated protein C [9] and antithrombin [10, 11] . Recent studies, however, have suggested a beneficial and physiologic role for coagulation during sepsis [2] . Formation of microthrombi in response to infection can reduce bacterial outgrowth, pointing to a role for coagulation in protective innate immunity, a concept referred to as immunothrombosis [2] . Multiple players have been implicated in immunothrombosis, among which are platelets [12, 13] , neutrophils [14] , neutrophil extracellular traps (NETs) [12, 15] , fibrin [16, 17] and PARs [18] . Yet, knowledge of the specific interactions and importance of individual components of the coagulation cascade necessary for immunothrombosis is limited. The protease thrombin is a crucial mediator of coagulation via fibrin formation [19] and platelet activation [20] , but also has a direct effect on inflammation via immune and endothelial cells [21] . Thrombin can enhance cytokine production [22, 23] , leukocyte recruitment [24, 25] and endothelial cell activation [23, 24] , which can all influence the pathogenesis of sepsis [3, 26] .
We here sought to elucidate the role of thrombin in the innate immune response during sepsis originating from a pulmonary infection, thereby mimicking a clinically common scenario [1] . We used an established murine model of pneumonia caused by the gram-negative bacterium Klebsiella (K.) pneumoniae, which frequently causes sepsis in humans [27] and in mice produces a gradually evolving localized infection that eventually disseminates to distant body sites [13] . Unlike models of sepsis associated with acute systemic inflammation, such as endotoxemia, this model of pneumonia and sepsis captures both the protective early local reaction and the subsequent injurious host response when bacteria have succeeded in spreading outside the lung. By administering the specific thrombin inhibitor dabigatran [28] in vivo and by in vitro experiments, we show that thrombin is an essential component of protective immunity during pneumonia-derived sepsis through mechanisms that involve fibrin polymerization and platelet-neutrophil interactions.
Methods

Animals
Specific pathogen-free C57Bl/6 mice (Charles River, Lyon, France) were housed in the Animal Research Institute Amsterdam facility under standard care. All experiments were conducted with female mice aged 8-12 weeks. The Institutional Animal Care and Use Committee of the Academic Medical Center approved all experiments.
Experimental study design Pneumonia and sepsis was induced by intranasal inoculation with K. pneumoniae serotype 2 (ATCC 43816; American Type Culture Collection, Manassas, VA, USA; 10 000 colony forming units [CFU]), as previously described [13] . Three days before induction of pneumonia and during the experiment, mice were fed ad libitum with dabigatran (10 mg g À1 dabigatran exilate [Pradaxa Ò ], Alkmaar, the Netherlands]) in AMII chow (Arie Blok, Woerden, the Netherlands), a dose adequate for thrombin inhibition [28, 29] , or control AMII chow. Mice were euthanized 12 or 44 h after induction of pneumonia (n = 8 per group); non-infected mice were sacrificed simultaneously (n = 4 per group). Bacterial quantification and storage of blood and organs were performed as previously described [13] . To assess the effect of dabigatran on survival, mice were observed for 10 days (n = 20 per group) and clinical signs were scored by an independent animal biotechnician, unaware of group allocation, as previously described [13] . The clinical sign score consisted of the parameters: solitude (0, absent; 1, present), posture (0, normal; 1, sphere), fur (0, normal; 1, pilo-erection), eyes (0, open; 1, closed; 2, dirty), alertness (0, normal; 1, slow; 2, apathetic; 3, non-responsive), pace (0, normal; 1, shaky; 2, collapse), respiration (0, normal; 1, heavy; 2, slow; 3, intermittent) and time to ascent when laid down (0, normal; 1, < 5 s; 2, > 5 s; 3, unresponsive).
Dabigatran levels
Mice were fed with dabigatran or control chow for 12 days. On days 2 and 12, dabigatran levels were measured in citrated plasma with the Hemoclot Thrombin inhibitor test (Hyphen BioMed, Neuville-sur-Oise, France) [29] .
Fibrinogen depletion
In a pilot, mice received intraperitoneally (i.p.) 1 IU or 3 IU ancrod per day (NIBSC, Potters Bar, UK) for 3 days and were sacrificed 1 day after the final administration. For infection experiments, mice were fed with dabigatran or control chow (see above) and treated i.p. with 3 IU ancrod per day or vehicle control for 3 days. Mice were infected after the second ancrod treatment and euthanized 40 h after induction of pneumonia (n = 8 per group).
determined by using rat anti-mouse-CD11b mAb (BD Biosciences, San Diego, CA, USA), rat anti-mouse-CD115 mAb (eBioscience, San Diego, CA, USA) and ratanti-mouse Ly-6 mAb (BD Biosciences) in combination with anti-CD61 mAb. Leukocyte activation was determined by geometric mean fluorescence intensity (MFI) of CD11b on Ly-6+ neutrophils. Human PAR1 was determined by anti-PAR1 mAb (R&D, Minneapolis, MN, USA) with anti-cd61 (eBioscience) or anti-cd66b (BD Biosciences).
Assays
Interleukin (IL)-6, tumor necrosis factor (TNF)-a, chemokine (C-C motif) ligand 2 (CCL2), elastase and IL-1b were determined using cytometric beads array multiplex assay (BD Biosciences) or by ELISA (R&D). Soluble Pselectin, soluble E-selectin, myeloperoxidase (MPO), C-X-C motif ligand (CXCL)1 and CXCL2 (all R&D) and thrombin-antithrombin complexes (TATc; Bio-connect, Huissen, the Netherlands) were determined by ELISA. Ddimer formation was determined using rabbit anti-mouse fibrinogen ab (MyBioSource, San Diego, CA, USA), at 180 kDa. Positive control for D-dimer was murine recalcified citrate plasma with Innovin 1 : 1000 (Baxter, Utrecht, the Netherlands) and 2 lg mL À1 tissue-type plasminogen activator (Actilyse; Boehringer Ingelheim) incubated for 1 h at 37°C. Levels of citrullinated histone 3 (CitH3) in plasma were determined by western blot using rabbit-anti-CitH3 (1 : 1500; Abcam, Cambridge, UK). Western blot results were quantified using densitometry with Adobe Photoshop (Adobe, San Jose, CA, USA). Aminotransferase (AST), alanine aminotransferase (ALT) and lactate dehydrogenase (LDH) were measured using a Roche Diagnostics c702 (Roche, Almere, the Netherlands). Hemoglobin concentrations were measured in lung homogenates at 410 nm by NanoDrop spectrophotometer (Thermo Fisher, Waltham, MA, USA). Cell-free DNA (cfDNA) in plasma was determined as previously described [30] .
Lung pathology
Four-micrometer paraffin embedded lung sections were stained with hematoxylin and eosin. Slides were coded and scored by a pathologist blinded for group identity. Seven parameters were scored 0-4: for the lung, interstitial inflammation, endotheliitis, bronchitis, edema, pleuritis, bleeding and thrombi. Scores were added together for the total histopathological score. To determine neutrophil influx in the lung, sections were stained with anti-mouse Gr-1 mAb (BD) as previously described [13] . Fibrin(ogen) staining on lung sections was performed using a goat anti-mouse fibrin(ogen) antibody (Accurate, Westbury, NY, USA) [31] . Expression was quantified by digital image analysis. Slides were scanned with the Olympus Slide system (Olympus dotSlide, Tokyo, Japan) and TIFF images were measured using Image J (NIH, Bethesda, MD, USA); the amount of positivity was expressed as percentage of the total lung surface. ; Worthington Biochem, Lakewood, CA, USA) was added. Additionally, platelet-rich plasma was prepared by centrifugation for 15 min at 180 9g, after which an aliquot was centrifuged twice for 20 min at 1560 9g to generate platelet-poor plasma. Neutrophils and peripheral blood mononuclear cells (PBMCs) were isolated with Polymorph prep (Elitech, Spankeren, the Netherlands) and mixed with platelet-rich or platelet-poor plasma (in a similar ratio to that in whole blood), and then Klebsiella (10 4 CFU mL À1 ) was added. After 2 h under shaking conditions, samples were carefully homogenized with a Bio-Gen-PRO200 homogenizer (PRO Scientific, Oxford, CT, USA) and bacterial loads were quantified by plating aliquots on blood agar plates and counted after 14 h incubation at 37°C.
Statistical analysis
Comparisons between groups were performed using the Kruskal-Wallis one-way analysis of variance test, and the Mann-Whitney U-test where appropriate. Survival was compared using the Kaplan-Meier method, followed by the log-rank test. Clinical observation scores were compared with a repeated measure analysis of variance. A non-linear line was fitted for the point graph of CFU and intensity of fibrin staining of each individual mouse and correlation were determined by Spearman's rho test. P values < 0.05 were considered statistically significant.
Results
Dabigatran impairs survival in K. pneumonia-induced pneumonia and sepsis
Mice were fed with dabigatran chow at a dose previously shown to be adequate for thrombin inhibition [28, 29] . Median dabigatran plasma levels reached 0.29 lg mL These levels have been documented to lead to prolonged activated partial thromboplastin time and reduced hemostasis [28] .
To investigate the impact of thrombin inhibition by dabigatran on mortality during pneumosepsis induced by K. pneumoniae, we performed an observational study in mice that had been placed on dabigatran or control chow 3 days earlier. Mice treated with dabigatran showed accelerated mortality (P < 0.005) and a more rapidly increasing clinical sign score (P < 0.0001) when compared with mice receiving control chow (Fig. 1A,B ).
Thrombin aids in containment of infection during Klebsiella pneumonia
To obtain insight into the mechanism by which thrombin inhibition impaired survival in Klebsiella pneumosepsis, we sacrificed mice 12 or 44 h after induction of pneumonia and measured bacterial outgrowth in lungs and distant organs (blood, liver and spleen). At 12 h after infection, Klebsiella was still mostly contained in the lung, with few mice showing signs of dissemination ( Fig. 1C-F ). Dabigatran and control mice did not differ in bacterial loads at this early time-point. In contrast, at 44 h dabigatran-treated mice showed increased bacterial burdens in lungs, blood and spleen ( Fig. 1C-F ; P < 0.005 and < 0.05 vs. control), with median bacterial loads that were 100-1000-fold higher than control mice. These results indicate that thrombin is crucial for host defense during Klebsiella-induced pneumosepsis, in particular during dissemination of bacteria from the lung. In spite of higher bacterial loads, dabigatran-treated mice did not show enhanced bleeding in lungs (Fig. S1 ), excluding this as a cause of accelerated mortality in these animals.
Thrombin inhibition does not impair leukocyte recruitment or activation, NET formation or cytokine production Reports using murine infection models have indicated a role for thrombin in leukocyte recruitment [32] . As leukocyte influx into the site of infection can aid in local host defense during pneumonia, we assessed neutrophil recruitment by measuring MPO in whole lung homogenates and by determining the number of Ly-6G-positive cells in lung tissue. Dabigatran did not influence neutrophil influx into the lungs ( Fig. 2A-C) . To assess the effect of thrombin inhibition on leukocyte activation, we measured MPO concentrations in plasma (granule release from neutrophils) and CD11b expression on blood neutrophils, which were similar between groups, as were neutrophil counts ( Fig. 2D-F) . In contrast, plasma MPO levels were even higher in dabigatran-treated mice at 44 h, most likely because of increased bacterial loads ( Fig. 2D ; P < 0.05 vs. control).
Neutrophil extracellular traps have been implicated as important mediators of bacterial killing and immunothrombosis [15] . We assessed NET formation by measuring citrullinated histone 3, cell-free DNA levels and elastase levels in plasma of infected mice [33] . CitH3 was up-regulated during infection, but was not different between groups at 12 h, when bacterial loads were still similar (Fig. 2G ,H,J,K; P < 0.05 vs. uninfected). At 44 h, when dabigatran mice showed increased bacterial loads, augmented CitH3 levels were seen ( Fig. 2I,L ; P < 0.005 vs. control). Similar results were found for cell-free DNA and elastase levels in plasma ( Fig. 2M,N ; P < 0.005 vs. control).
Additionally, inhibition of NET formation in human whole blood with Cl-amidine [34] did not affect growth of Klebsiella in coagulating conditions (Fig. 2O) . DNAse also did not affect ex vivo Klebsiella growth (Fig. S2) .
Thrombin can alter cytokine production via PARs [23] . Dabigatran treatment was associated with increased Bacterial counts were determined in lungs (C), blood (D), spleen (E) and liver (F). Horizontal lines represent medians. ***P < 0.0001, **P < 0.005, *P < 0.05 vs. control mice. cytokine and chemokine levels in plasma and lungs at 44 h (Fig. S3) , probably because of increased bacterial loads. Dabigatran did not have a clear effect on cytokine levels at 12 h after infection, when bacterial loads were still similar, with both reduced and increased levels in dabigatran-treated mice (Fig. S3) . Collectively, these results suggest that thrombin inhibition does not impair the host defense during Klebsiella pneumonia by impeding neutrophil functions or cytokine production. In addition, our data suggest that NETs are not important for Klebsiella growth inhibition.
Thrombin inhibition impairs host defense via fibrin formation and both thrombin and fibrin polymerization contribute to growth inhibition ex vivo Thrombin initiates clotting by the conversion of fibrinogen into fibrin [19] . By using fibrin staining, we show that infection induced fibrin formation in the lungs (Fig. 3A,B ; P < 0.05 vs. uninfected). In the control group, mice with higher bacterial burdens presented with higher levels of fibrin deposition, whereas in dabigatrantreated mice this association was absent ( Fig. 3C,D ; P < 0.05 for correlation between bacterial loads and fibrin deposition in controls). Consistent with its anticoagulant effect, dabigatran-treated mice demonstrated reduced D-dimer levels and TATc levels in lungs at 12 h, when bacterial loads were still similar (Fig. 3E,G,I ; P < 0.005 vs. control). At 44 h, when bacterial loads were significantly higher in the dabigatran-treated mice, there were no differences between groups in D-dimer levels, and even higher TATc levels in dabigatran-treated mice (Fig. 3F,H,I ).
To further elucidate the role of thrombin and fibrin in the host response to Klebsiella, we treated mice with dabigatran, the fibrinogen depleting agent ancrod [16] or a combination of them. Ancrod administration reduced fibrinogen levels in plasma to < 10% (Fig. 4A,B) . In accordance with the experiments reported above, dabigatran-treated mice showed increased bacterial burdens in lungs and distant organs (shown for lungs and liver in Fig. 4C,D ; P < 0.005 and < 0.05 vs. control). Mice treated with ancrod also showed increased bacterial burdens in lungs and distant organs (Fig. 4C,D ; P < 0.005 and < 0.05 vs. control). In mice treated with ancrod, dabigatran did not additionally affect bacterial burdens (Fig. 4C,D) . These results suggest that thrombin is important for containment of infection during Klebsiellainduced pneumonia, and that this effect is largely mediated via the effect of thrombin on fibrin formation. To obtain insight into possible antibacterial effects of thrombin and fibrin, we performed bacterial growth inhibition assays in human whole blood (Fig. 4E ). Fresh citrated human whole blood was recalcified to start clotting and anticoagulated either by the thrombin inhibitor hirudin [35] or with fibrin polymerization inhibitor Gly-Pro-ArgPro [36] . As dabigatran needs to be metabolized in vivo, we used hirudin (also a direct thrombin inhibitor [35] ) to investigate the effects of thrombin on Klebsiella outgrowth in vitro. Both inhibition of thrombin and fibrin polymerization resulted in increased growth of Klebsiella in whole blood ( Fig. 4E ; both P < 0.005 vs. clotted blood). Importantly, hirudin-anticoagulated blood showed increased Klebsiella outgrowth when compared with blood anticoagulated with Gly-Pro-Arg-Pro ( Fig. 4E ; P < 0.05). Collectively, these results indicate a role for both thrombin and fibrin in inhibiting Klebsiella outgrowth ex vivo as well as in vivo. Klebsiella growth in citrated blood was lower compared with medium alone, but similar to growth in recalcified hirudin blood (Fig. S4) . Dabigatran exilate did not influence Klebsiella growth in the absence of blood (Fig. S5) .
Neutrophils, platelet-neutrophil interactions and PAR1 are important for inhibition of Klebsiella outgrowth Immunothrombosis has been described as an interplay in which coagulation, immune cells and platelets work together to restrict bacterial outgrowth [14] . To study the interaction between these components during Klebsiella outgrowth, we isolated platelet-poor plasma, platelet-rich plasma, neutrophils and PBMCs from human whole blood and incubated mixed collections of cells with viable Klebsiella in coagulating conditions. Mainly neutrophils, but also PBMCs, inhibited bacterial outgrowth ( Fig. 5A ; P < 0.05 vs. platelet-rich plasma). Considering that thrombin is a potent agonist of PAR1 [23] , we assessed the role of this receptor by inhibiting its activation with the specific PAR1 inhibitor voparaxar [37] in clotting blood (in which thrombin is present). PAR1 inhibition increased Klebsiella outgrowth ( Fig. 5B ; P < 0.005 vs. clotting blood with vehicle control). Platelets are crucial for primary hemostasis, but also influence host defense [13] . As thrombin is a potent activator of platelets [20] , we investigated the role of platelets in Klebsiella outgrowth ex vivo. Platelets did not influence Klebsiella outgrowth in the absence of leukocytes, as reflected by similar Klebsiella outgrowth in platelet-rich plasma and platelet-poor plasma (Fig. 5C) . However, platelets significantly potentiated neutrophil-mediated growth inhibition of Klebsiella in coagulating conditions ( Fig. 5C ; P < 0.005 for the difference between platelet-rich and at least two independent experiments and six duplicates per condition. Data are represented as bars depicting median interquartile range or box-and-whisker plots depicting the smallest observation, lower quartile, median, upper quartile and largest observation. *P < 0.05, **P < 0.005, ***P < 0.0005.
platelet-poor plasma in the presence of neutrophils). When thrombin activity was inhibited by hirudin, platelets were less capable of restricting bacterial outgrowth ex vivo (Fig. 5D ). From these results it was not yet clear, however, whether platelet or neutrophil PAR1 is important for restricting bacterial outgrowth. We therefore compared Klebsiella outgrowth in neutrophil cultures with or without platelets in coagulating conditions, after pre-incubation with voparaxar (inhibiting PAR1 activation) or vehicle control. Voparaxar did not influence Klebsiella growth in cultures of neutrophils in platelet-poor plasma; however, voparaxar-treated platelet-rich plasma with neutrophils showed increased bacterial outgrowth ex vivo (Fig. 5E ). Platelets also showed higher PAR1 expression than neutrophils (Fig. S6) . These results suggest that thrombin limits Klebsiella outgrowth by effects that require platelet-neutrophil interactions and platelet PAR1.
Thrombin inhibition reduces platelet-leukocyte complexes and endothelial cell activation but does not prevent sepsisinduced thrombocytopenia
As platelets enhanced neutrophil-mediated growth inhibition of Klebsiella in vitro, we assessed the effect of thrombin inhibition on platelet-neutrophil formation in vivo.
Twelve hours after infection, platelet-neutrophil complexes were reduced in dabigatran-treated mice compared with controls ( Fig. 6A,B ; P < 0.005 vs. controls). Sepsis induced thrombocytopenia, but this was not mitigated by thrombin inhibition (Fig. 6C) . In dabigatran-treated mice, plasma concentrations of soluble P-selectin were reduced 12 h after infection ( Fig. 6D ; P < 0.005 vs. controls).
Considering that P-selectin is produced by both platelets and endothelial cells [38] and thrombin can activate endothelial cells [23] , we also determined soluble E-selectin, a marker of endothelial cell activation [39] . Thrombin inhibition by dabigatran reduced plasma soluble E-selectin levels at 12 h, when bacterial loads were still similar ( Fig. 6E ; P < 0.05 vs. control); this effect was not present at 44 h. These results suggest that thrombin influences platelet-leukocyte formation and, considering the similar effects of dabigatran on plasma soluble E-and P-selectin, endothelial cell activation during Klebsiella infection.
Thrombin inhibition increases end-organ damage during Klebsiella sepsis
To assess the effect of thrombin inhibition on organ damage, we examined organ injury during late-stage gramnegative pneumosepsis (i.e. shortly before the first deaths occurred at 44 h). Activation of coagulation during infection can lead to microvascular failure and multiple organ failure [4] . On the other hand, we here show that thrombin is important for host defense. In line with this, thrombin inhibition was associated with increased distant organ damage ( Fig. 7A-E) . Specifically, dabigatran did not influence local lung pathology (Fig. 7A,B) but significantly increased plasma levels of lactate dehydrogenase (LDH, indicative of cell injury; Fig. 7C ). Plasma AST and ALT (indicative of hepatocellular injury) tended to be higher in dabigatran-treated mice (Fig. 7D,E) . Increased organ failure may contribute to the increased mortality seen in dabigatran-treated mice.
Discussion
We investigated the role of thrombin during gram-negative pneumonia and sepsis by infecting mice treated with the thrombin inhibitor dabigatran or control chow with the common human sepsis pathogen K. pneumoniae. Our main findings are that thrombin inhibition resulted in enhanced bacterial outgrowth and dissemination and accelerated mortality. Further in vivo and in vitro experiments revealed that thrombin improved the host defense against Klebsiella via thrombin-induced fibrin generation and subsequent polymerization, and stimulation of neutrophil-mediated bacterial growth inhibition at least in part through an interaction with platelets and platelet PAR1.
Thrombin inhibition reduced fibrin formation induced by pneumonia, and both thrombin and fibrin contributed to the host defense against Klebsiella. In human whole blood, thrombin inhibition had a stronger effect on Klebsiella growth than inhibition of fibrin polymerization, suggesting that in vitro part of the thrombin-mediated effect is also independent of fibrin network formation. This fibrin independent effect was, however, modest, and in vivo the effect of fibrin was dominant. In vivo, fibrin formation can aid in local containment of bacteria, but also in vitro fibrin formation inhibited Klebsiella growth. In vitro, physical encasement of bacteria or direct activation of leukocytes or platelets by fibrin could play a role [22, 40] . In less severe infections accompanied with less fibrin formation, the direct effect of thrombin may play a role in local host defense against bacteria. We were also able to show that the effect of thrombin in vitro was partly mediated via platelets, and in line with this our group has shown that platelets are crucial for host defense against Klebsiella [13] .
Platelets can potentiate neutrophil functions [41] . We found that, although human platelets by themselves did not influence bacterial growth, they increased neutrophil- mediated Klebsiella growth inhibition in clotting conditions, but not when thrombin or PAR1 was inhibited. Also, dabigatran-treated mice showed reduced plateletneutrophil complexes. Together these results suggest a role for thrombin in augmenting the potentiating effect of platelets on neutrophil-mediated bacterial growth inhibition. In line with this, platelet P-selectin, an important mediator of platelet-leukocyte interactions, has previously been shown to contribute to innate defense against Klebsiella [38] . Thrombin inhibition also reduced levels of soluble E-selectin, reflecting decreased endothelial cell activation. Previous reports have suggested that increased endothelial cell activation might contribute to immunothrombosis [2] . In contrast to previous studies [24, 32] , neutrophil recruitment was not different in dabigatran-treated mice, suggesting that leukocyte influx during Klebsiella pneumosepsis depends on other stimuli than thrombin. Likewise, dabigatran did not impact NET formation. NETs have been identified as crucial players in immunothrombosis [2, 14] and are at close interplay with coagulation [14] . In vivo, thrombin inhibition did not reduce NET formation, and in vitro, NET inhibition did not influence Klebsiella growth. Collectively, these data suggest that NETs are not important for Klebsiella growth inhibition, which is consistent with a previous report [13] .
Our results are in line with other animal studies (using peritonitis and skin infection models of Escherichia coli, Staphylococcus (S.) aureus and Group A streptococci) that have shown a role for fibrin in limiting bacterial dissemination [14, 16, 17, 42] . However, during skin infection or endocarditis caused by S. aureus, interaction with fibrin aids in S. aureus agglutination and survival, and thrombin inhibition was shown to be beneficial [43] [44] [45] [46] . These studies show that thrombin inhibition during infection may either be beneficial or detrimental, depending on the specific pathogen and site of infection. Moreover, our findings contrast with previous reports showing that inhibition of coagulation can improve outcome during systemic hyperinflammation and fulminant sepsis by preventing amplification of inflammation or microvascular failure [5, 10] . These earlier investigations differ from our study in that high-dose challenges were used that caused acute and strong activation of both inflammatory and procoagulant pathways; in these experimental settings bacteria were either not present (e.g. systemic inflammation by endotoxin administration [5, 7] ) or administered in such a high dose that a potential protective role of coagulation could not be detected [9, 10] . In human sepsis patients, activation of coagulation and fibrin deposition can lead to microvascular failure and subsequent multiple organ failure [4] . So far, studies inhibiting coagulation during pneumonia and sepsis (e.g. by using heparin or antithrombin) have found no beneficial effect on mortality [47, 48] . We here show that in murine Klebsiella pneumonia-derived sepsis, thrombin inhibition increased mortality and end-organ damage. Hence, these data suggest that thrombin inhibition would not be beneficial as a treatment for severe gram-negative pneumonia-derived sepsis.
In conclusion, we found that thrombin inhibition by dabigatran is associated with an accelerated mortality and impaired host defense during Klebsiella pneumonia-derived sepsis. Thrombin formation limited bacterial growth and spreading through inducing fibrin formation and by enhancing the effect of platelets on neutrophil-mediated bacterial growth inhibition via a PAR1-dependent mechanism. These results exemplify the tight interaction between coagulation and antibacterial defense, and suggest that thrombin generation in response to infection should be viewed as a component of a protective innate immune response during Klebsiella pneumonia-derived sepsis. Table S1 . Dabigatan levels measured by Hemoclot test. Figure S1 . Dabigatran treatment does not result in increased lung bleeding. Figure S2 . Neutrophil extracellular trap inhibition by DNAse does not alter Klebsiella outgrowth in human whole blood. Figure S3 . Thrombin inhibition by dabigatran does not have a clear effect on cytokine levels. Figure S4 . Klebsiella growth in anticoagulated blood is restricted compared with growth in medium. Figure S5 . Dabigatran exilate does not directly influence Klebsiella growth in the absence of human whole blood. Figure S6 . PAR1 expression on human platelets and neutrophils.
